AR012593A1 - SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents
SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCTInfo
- Publication number
- AR012593A1 AR012593A1 ARP980101885A ARP980101885A AR012593A1 AR 012593 A1 AR012593 A1 AR 012593A1 AR P980101885 A ARP980101885 A AR P980101885A AR P980101885 A ARP980101885 A AR P980101885A AR 012593 A1 AR012593 A1 AR 012593A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- substituted
- phenyl
- alkoxy
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Abstract
Pirrolopiridinas substituidas de formula (I), en la cual: R1 es amino, alquilamino C1-5, dialquilamino C1-5, hidroxi, alcoxi C1-5,alquilcarbonilamino C1-5, fenilcarbonilamino sustituido donde los sustituyentes fenilo se seleccionan entre elgrup o que consiste en halogeno, hidrogeno,alquilo C1-5 y alcoxi C1-5, arilalquilamino C1-3 o R7R8NCH=N-,donde R7 y R8 son seleccionados independientemente entre el grupo que consiste en hidrogeno yalquilo C1-5; R2 es hidrogeno, halogeno,fenilalquilo C1-5 o fenilalquilo sustituido donde los sustituyentes fenilo se seleccionan entre el grupo queconsiste en halogeno, hidrogeno, alcoxi C1-5 y alquilo C1-5; R3 es hidrogeno, alcoxi C1-5, feniloxi sustituido, (donde lossustituyentes fenilo se seleccionan entre el grupo que consiste en halogeno, hidrogeno, alcoxi C1-5), fenilalquiloxi sustituido C1-5 (donde los sustituyentes fenilo se seleccionanentre el grupo que consiste en halogeno, hidrogeno, alcoxi C1-5 yalquilo C-15) ; R4 es -N- o -C-; R5 es fenilo o fenilo sustituido donde los sustiyentesse seleccionan entre uno a tres miembros del grupo que consiste en halogeno, alquilo C1-5 y alcoxi C1-5; R6 es hidrogeno, alquilo C1-5 o dialquilaminoC1-5; ylas sales farmacéuticamente a ceptables de los mismos; composiciones farmacéuticas que las contienen, procedimiento para su preparacion, el uso delos mismos en la manufactura de un medicamento e intermediarios utilizados en su fabricacion.Los compuestos inhiben la produ ccion de una cantidad decitocinas inflamatorias, son utiles en el tratamiento de enfermedades asociadas.Substituted pyrrolopyridines of formula (I), in which: R1 is amino, C1-5 alkylamino, C1-5 dialkylamino, hydroxy, C1-5 alkoxy, C1-5 alkylcarbonylamino, substituted phenylcarbonylamino where phenyl substituents are selected from the group or it consists of halogen, hydrogen, C1-5alkyl, and C1-5alkoxy, arylalkyl-C1-3alkyl, or R7R8NCH = N-, where R7 and R8 are independently selected from the group consisting of hydrogen and C1-5alkyl; R2 is hydrogen, halogen, phenyl-C1-5-alkyl or substituted phenylalkyl where the phenyl substituents are selected from the group consisting of halogen, hydrogen, C1-5-alkoxy and C1-5-alkyl; R3 is hydrogen, C1-5 alkoxy, substituted phenyloxy, (where phenyl substituents are selected from the group consisting of halogen, hydrogen, C1-5 alkoxy), substituted phenyl-C1-5alkyloxy (where phenyl substituents are selected from the group consisting of in halogen, hydrogen, C1-5 alkoxy and C-15 alkyl); R4 is -N- or -C-; R5 is phenyl or substituted phenyl where the substituents are selected from one to three members from the group consisting of halogen, C1-5 alkyl, and C1-5 alkoxy; R6 is hydrogen, C1-5 alkyl, or C1-5 dialkylamino; and the pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing them, procedure for their preparation, their use in the manufacture of a medicine and intermediates used in their manufacture. The compounds inhibit the production of a quantity of inflammatory cytokines, they are useful in the treatment of associated diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4424497P | 1997-04-24 | 1997-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012593A1 true AR012593A1 (en) | 2000-11-08 |
Family
ID=21931293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101885A AR012593A1 (en) | 1997-04-24 | 1998-04-23 | SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR012593A1 (en) |
| AU (1) | AU7132998A (en) |
| WO (1) | WO1998047899A1 (en) |
| ZA (1) | ZA983452B (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
| DE69728688T2 (en) | 1996-11-19 | 2004-08-19 | Amgen Inc., Thousand Oaks | ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLE AS AN ANTI-FLAMMING AGENT |
| PL340412A1 (en) | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| HUP0004947A2 (en) * | 1997-11-14 | 2002-03-28 | Sankyo Co., Ltd. | Pyridylpyrrole derivatives |
| AU4694999A (en) * | 1998-08-06 | 2000-02-28 | Warner-Lambert Company | Use of thiazolidinedione derivatives for the treatment or prevention of cataracts |
| CA2346665A1 (en) | 1998-10-07 | 2000-04-13 | Smithkline Beecham Corporation | Novel treatment for stroke management |
| AU1909200A (en) | 1998-11-04 | 2000-05-22 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| ATE311385T1 (en) * | 1999-10-27 | 2005-12-15 | Novartis Pharma Gmbh | THIAZOLE AND IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS |
| GB9930698D0 (en) * | 1999-12-24 | 2000-02-16 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| CA2699568C (en) | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
| WO2001057018A1 (en) * | 2000-02-02 | 2001-08-09 | Abbott Laboratories | Azaazulene inhibitors of p38 map kinase and tnf-alpha |
| PE20020506A1 (en) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| JP2005534618A (en) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | 7-azaindole as a C-JUNN-terminal kinase inhibitor for neurodegenerative diseases |
| SG135051A1 (en) * | 2002-06-20 | 2007-09-28 | Aventis Pharma Ltd | Azaindoles |
| WO2004004725A2 (en) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| JP4787150B2 (en) * | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | JNK inhibitor |
| GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| EP1628975A2 (en) | 2003-05-16 | 2006-03-01 | Eisai Co., Ltd. | Jnk inhibitors |
| WO2005051301A2 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| GB0405055D0 (en) * | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US20080300267A1 (en) * | 2005-05-16 | 2008-12-04 | Barun Okram | Compounds and Compositions as Protein Kinase Inhibitors |
| GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| CA2627497C (en) | 2005-10-28 | 2014-10-14 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof |
| CL2007002617A1 (en) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO. |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| AU2009257635A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| MY172424A (en) | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
| BR112012012156A2 (en) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compounds and methods for kinase modulation, and indications for this |
| TR201816421T4 (en) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Compounds and methods for kinase modulation and their indications. |
| AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
| US20130158049A1 (en) * | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 7-azaindole inhibitors of crac |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| FR3001219A1 (en) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | KINASE INHIBITORS |
| US10457678B2 (en) | 2015-10-13 | 2019-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871444A4 (en) * | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
-
1998
- 1998-04-17 WO PCT/US1998/007831 patent/WO1998047899A1/en active Application Filing
- 1998-04-17 AU AU71329/98A patent/AU7132998A/en not_active Abandoned
- 1998-04-23 ZA ZA9803452A patent/ZA983452B/en unknown
- 1998-04-23 AR ARP980101885A patent/AR012593A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA983452B (en) | 1999-10-25 |
| WO1998047899A1 (en) | 1998-10-29 |
| AU7132998A (en) | 1998-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012593A1 (en) | SUBSTITUTED PYRROLYPYRIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| HUP0203438A2 (en) | 5-(2-substituted-5-heterocyclysulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0300894A2 (en) | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use | |
| AR029383A1 (en) | SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS | |
| AR031680A1 (en) | USE OF QUINUCLIDINE ACRYLAMIDS FOR THE PREPARATION OF MEDICINES, COMPOUNDS AND PHARMACEUTICAL COMPOSITION | |
| AR036032A1 (en) | COMPOUND DERIVED FROM QUINOLINA, COMPOSITION THAT INCLUDES IT; USE OF THE SAME IN THE MANUFACTURE OF MEDICINES, PROCESS TO PREPARE IT, AND METHOD TO DETECT AND SELECT AN AGENT THAT MODULATES THE ACTIVITY OF MIF | |
| HUP0401307A2 (en) | New indole derivatives with 5-ht6 receptor affinity, process for their preparation and pharmaceutical compositions containing them | |
| CR7743A (en) | NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
| ECSP066383A (en) | DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES | |
| AR063211A1 (en) | DERIVATIVES OF 3- (PIRIDIN-3-IL) ACRILAMIDE AND 3- (PIRIDIN-3-IL) PROPIONAMIDE, A METHOD FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ASSOCIATED DISEASES WITH THE VANILOID RECEIVER. | |
| AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
| NO20055421L (en) | Quinoline derivatives as phosphodiesterase inhibitors | |
| CA2628131A1 (en) | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods | |
| ATE370138T1 (en) | NEW IMIDAZOPYRIDINES AND THEIR USE | |
| HUP0302474A2 (en) | Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use | |
| AR055916A1 (en) | DERIVATIVES OF DIHYDROBENZOFURAN, USES OF THE SAME IN THE PREPARATION OF A PHARMACEUTICAL MEDICINAL AND COMPOSITION | |
| ATE557002T1 (en) | COMPOUNDS WITH CALCIMETIC ACTION | |
| UY29427A1 (en) | SUBSTITUTED DERIVATIVES OF 2,3,4,5- TETRAHIDRO-1H-PIRIDO (4,3-B) INDOL, COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS | |
| AR035235A1 (en) | HETEROCICLILOXI DERIVATIVES -, - TIOXI- AND -AMINOBENZAZOL AS 5-HYDROXITRIPTAMINE-6 LINES, A PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| NO20070837L (en) | Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer. | |
| DK1730144T3 (en) | Substituted 1,4,8-triazaspiro [4.5] decan-2-one compounds | |
| RU99101081A (en) | MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORS | |
| AR054707A1 (en) | DERIVATIVES OF OCTAHIDROPIRROLO 3,4-C PIRROL, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| HUP0003413A2 (en) | New fused pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| AR032607A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF HYDROXIEICOSATETRAENOATE, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DRY EYE DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |